The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
Recruitment status was: Not yet recruiting
Indoxyl sulfate (IS) is a uremic toxin that accelerates the progression of chronic kidney disease (CKD). AST-120 (Kremezin®; Kureha Corporation, Tokyo, Japan) removes indole, which is the precursor of IS, in the intestine, and reduces the accumulation of IS. This drug has been shown to retard the deterioration of renal function in CKD patients through reducing the levels of IS.
IS was reported to promote aortic calcification and stimulate the proliferation of vascular smooth muscle cells (VSMC). IS also inhibits endothelial proliferation and wound repair. With this background, the investigators will performed the study whether AST-120 improve the endothelial dysfunction in CKD patients.
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease|
- Changes of FMD(Flow Mediated Dilatation) [ Time Frame: 6 months ]FMD (Flow Mediated Dilatation): percent change of FMD response to hyperemia and after sublingual nitroglycerin on brachial artery.
- Level of Indoxyl Sulfate [ Time Frame: 3 months, 6 months ]
|Study Start Date:||September 2010|
|Estimated Study Completion Date:||December 2011|
|Estimated Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
AST-120 administration 2g three times a day
AST-120 2g three times a day
Other Name: AST-120 (Kremezin) 2g three times a day
No Intervention: Control
Control Chronic Kidney disease stage 3,4
Please refer to this study by its ClinicalTrials.gov identifier: NCT01157260
|Korea, Republic of|
|Ewha Womans University Mokdong Hospital|
|Seoul, Korea, Republic of|
|Principal Investigator:||Duk-Hee Kang, MD. PhD.||Ewha Womans University|